| PROGRAM |
PRECLINICAL
PHASE 1
PHASE 2
|
PARTNER | TERRITORY |
|---|---|---|---|
|
Type 1 Diabetes
|
|
|
|
|
Psoriasis
|
|
|
|
|
Cystic Fibrosis Related Diabetes (CFRD)
|
|
|
|
|
Type 1 Diabetes Prevention
|
|
|
|
|
|
|
|
|
| Partnered Programs | |||
|
Type 2 Diabetes
|
|
Asia excluding Japan (ROW retained)
|
|
|
Primary Mitochondrial Myopathy
|
|
Worldwide
|
|
|
COPD/Psoriasis/Atopic Dermatitis
|
|
Asia excluding Japan (ROW retained)
|
|
|
Azeliragon (RAGE)
|
Cancer
|
|
Worldwide
|
|
Renal Diseases
|
Anteris Bio
|
Worldwide
|
Our programs are directed at treating metabolic diseases to minimize their long-term complications through end-organ protection.